DeNovaMed
Investment

DeNovaMed is an early-stage pharmaceutical company specializing in new therapeutic approaches to combat bacterial infections. DeNovaMed's founders used computer-aided drug design to develop a new class of compounds with the potential to treat infections caused by drug-resistant bacteria, or “superbugs.” The company plans to evaluate its best compounds in animal models of infection, with an ultimate goal of bringing to market a truly new antibiotic.

5850/5980 University Avenue
Goldbloom Building, 3rd floor
Halifax, NS B3K 6R8
Canada
902.470.7523